Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-centre, Open-label, Expanded Access Program of 900mg Intravenous (i.v.) Spesolimab in Patients With Generalized Pustular Psoriasis (GPP) Presenting With a Flare

NCT05239039 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT05239039
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05239039 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-centre, Open-label, Expanded Access Program of 900mg Intravenous (i.v.) Spesolimab in Patients With Generalized Pustular Psoriasis (GPP) Presenting With a Flare
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
March 15, 2022
Completion date
July 17, 2023
Enrollment
39 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

generalized pustular psoriasis